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 ABSTRACT 
 The objective of the conducted meta-analysis was 
to assess the efficacy of the treatment of bovine endo-
metritis with PGF2α by statistical means. Postpartum 
uterine infections have a high prevalence and a very 
negative effect on reproductive performance in dairy 
cattle. Because of a wide discordance between research 
results, a meta-analysis of the efficacy of the treatment 
of bovine endometritis with PGF2α was conducted. A 
comprehensive literature search was performed using 
online databases to reveal a total of 2,307 references. 
In addition, 5 articles were retrieved by reviewing ci-
tations. After applying specific exclusion criteria and 
evaluating specific evidence parameters, 5 publications, 
comprising 6 trials, were eligible for being analyzed 
by means of meta-analysis. Data for each trial were 
extracted and analyzed using meta-analysis software 
Review Manager (version 5.1; The Nordic Cochrane 
Centre, Copenhagen, Denmark). Estimated effect sizes 
of PGF2α were calculated on calving to first service and 
calving to conception interval. Prostaglandin F2α treat-
ment of cows with chronic endometritis had a negative 
effect on both reproductive performance parameters. 
Heterogeneity was substantial for calving to first ser-
vice and calving to conception interval [I2 (measure of 
variation beyond chance) = 100 and 87%, respectively]; 
therefore, random-effects models were used. Sensitivity 
analysis as well as subgroup analysis showed that the 
performance of randomization was influential in modi-
fying effect size of PGF2α treatment. The funnel plot il-
lustrated a publication bias toward smaller studies that 
reported a prolonged calving to conception interval 
after a PGF2α treatment. We conclude that the inves-
tigation of this subject by means of meta-analysis did 
not reveal an improvement of reproductive performance 
of cows with endometritis after treatment with PGF2α. 
Furthermore, there is a shortage of comparable high 
quality studies investigating reproductive performance 
after PGF2α treatment of cows with chronic endome-
tritis. 
 Key words:   meta-analysis ,  endometritis ,  prostaglan-
din F2α ,  dairy cow 
 INTRODUCTION 
 Postpartum uterine infections are a frequent disorder 
in dairy cattle with a prevalence of up to 57.7% (Shel-
don, 2009). In addition, they are reported to have an 
immense negative effect on reproductive performance 
resulting in high opportunity costs for the farmers 
(Plaizier et al., 1998; LeBlanc et al., 2002; LeBlanc, 
2008). 
 Clinical endometritis in cattle is defined as the 
presence of a purulent (>50% pus) uterine discharge 
detectable in the vagina 21 d or more postpartum or 
mucopurulent (approximately 50% pus, 50% mucus) 
discharge detectable in the vagina after 26 d postpar-
tum (Sheldon et al., 2006). 
 The amount of literature addressing the treatment of 
endometritis is huge and this subject has been reviewed 
by several authors (Gilbert and Schwark, 1992; Olson, 
1996; Azawi, 2008; Lefebvre and Stock, 2012). Never-
theless, the treatment of endometritis is still an issue 
of considerable controversy (Arlt et al., 2009; Dubuc 
et al., 2011). This may be due to the wide variety of 
therapies available for endometritis, including systemic 
or local antibiotics, PGF2α, and estradiol. Because the 
rate of self-cure is reported to range from 92% in wk 1 
to 25% in wk 7 postpartum (Falkenberg and Heuwieser, 
2005; Hirsbrunner et al., 2006), some authors question 
the necessity of any treatment at all. However, lim-
ited information exists on the proportions of cows that 
spontaneously recover (Dubuc et al., 2011). 
 The effect of a treatment with PGF2α or its analogs 
within 40 d after calving on reproductive performance 
has been investigated in several studies (Haimerl et al., 
2011). Remarkably, wide disparity exists between the 
results obtained (Burton and Lean, 1995). Young et al. 
(1984), for instance, reported a significant improvement 
in the first-service conception rates of 64 cows treated 
with PGF2α compared with 64 untreated controls. 
Another study conducted by Macmillan et al. (1987) 
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including 1,813 cows could not support these findings. 
According to a recent study conducted by Dubuc et al. 
(2011), an administration of PGF2α at both 5 and 7 wk 
postpartum did not mitigate the effects of cytological 
endometritis or purulent vaginal discharge on repro-
ductive performance. Thus, the authors postulate that 
clinical approaches to treatment of chronic postpartum 
reproductive tract infection and inflammation should 
be reassessed.
The unmanageable amount of medical information 
was criticized by Cochrane as early as 1972 (Cochrane, 
1972). He also complained about the lack of reliable 
summaries of available findings, such as meta-analyses. 
Such situations lead to difficulties in making decisions 
on the basis of current and valid information (Co-
chrane, 1972). Meta-analyses are systematic summaries 
of a large collection of results from individual studies 
and statistical analysis of those results from multiple 
individual studies (Glass, 1976). According to Eisend 
(2004), the prototypical meta-analysis should undergo 
the following 5 steps. First, a clinical question should 
be clearly formulated, and then a systematic and 
comprehensive search for relevant literature must be 
conducted. In the third step, data from the included 
literature are extracted and evaluated according to pre-
defined parameters. Then, the extracted data are com-
bined by using statistical techniques to obtain a pooled 
estimate of the treatment effect (Barker and Carter, 
2005). Finally, findings should be visualized (e.g., by 
forest plots) and critically interpreted. In conclusion, a 
meta-analysis is the statistical combination of at least 
2 studies to generate an estimate of the magnitude of 
the effect of the intervention under investigation (Lam 
and Kennedy, 2005). Consequently, the results of meta-
analyses are said to provide the greatest reliability when 
applied to the entire population (Arlt and Heuwieser, 
2005). The principal aim of a meta-analysis is to pro-
vide an objective quantitative assessment of previously 
published data as well as to increase the precision of 
the estimate of a treatment effect by increasing the 
sample size and thus increasing the statistical power 
(Lean et al., 2009). Furthermore, meta-analyses can be 
conducted to identify and investigate heterogeneity in 
the results of the included studies, based on factors 
such as the design and sample variables. Finally, meta-
analyses can be executed for the purpose of resolving 
conflicts among studies and developing new directions 
for research (L’Abbé et al., 1987; Henry and Wilson, 
1992; Wilson and Henry, 1992).
Because of the frequent occurrence of postpartum 
uterine infections, the associated economic impact, and 
a wide discordance between research results concerning 
therapy, a meta-analysis of the efficacy of the treatment 
of bovine endometritis with PGF2α was conducted.
MATERIALS AND METHODS
A comprehensive literature search was conducted 
on August 4, 2010, utilizing the search engine Vetseek 
(http://www.vetseek.info) and the databases Pubmed 
(http://www.pubmed.gov), Medline (http://www.
medline.de), and Animal Production (http://www.
ovid.com/site/catalog/DataBase/22.jsp) to identify 
literature related to the treatment of endometritis with 
prostaglandin in dairy cattle. The search terms “en-
dometritis AND cattle” and “endometritis AND cattle 
AND prostaglandin” were used to include all articles 
addressing the treatment of bovine endometritis with 
PGF2α. In addition, we carried out a systematic review 
of citations in the retrieved papers.
Selection by Inclusion and Exclusion Criteria
Specific exclusion criteria were defined to exclude 
studies that were not written in English or German 
or did not focus on chronic endometritis; that is, oc-
curring on and after 21 d after parturition (Sheldon 
et al., 2006). In addition, studies in which the animals 
received concomitant treatments with medications 
other than PGF2α were excluded. Book chapters, case 
studies, review articles, and abstracts were excluded. 
Furthermore, publications describing etiological, epide-
miological, microbiological, or nutritional results, clini-
cal symptoms, or diagnostic procedures were rejected. 
Articles not meeting the inclusion criteria due to in-
correct indexing and those not obtainable through the 
internet, bibliographies, or interlibrary lending services 
were excluded as well. If multiple publications were 
retrieved that described the same trial, those contain-
ing the least information were regarded as duplicates 
and excluded. Retrieval and management of references 
was performed with Endnote (version X3 for Windows, 
Thomson Reuters, New York, NY).
To examine quality and comparability, the remaining 
publications were evaluated according to various evi-
dence parameters, utilizing an evaluation form developed 
by Arlt et al. (2010) and recently validated by Simoneit 
et al. (2011). Relevant criteria of the study design such 
as sample size, the involvement of control groups (i.e., 
untreated, placebo-treated, treated with another drug), 
blinding, and randomization were considered. Inclusion 
criteria to be considered for the meta-analytic investiga-
tion were the presence of an untreated control group 
and the calculation of calving to first service interval 
(CFSI) or calving to conception interval (CCI) as well 
as the respective standard deviations.
Statistical Analysis
Data for each trial meeting those criteria were ex-
tracted and analyzed using meta-analysis software Re-
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view Manager (version 5.1, 2011; The Nordic Cochrane 
Centre, Copenhagen, Denmark).
Estimated effect sizes of PGF2α were calculated on 
CFSI and CCI applying the effect size method (Hedges 
and Olkin, 1985). The effect size is the difference be-
tween the treatment and control groups for the number 
of days open, divided by the pooled standard devia-
tion (Hedges and Olkin, 1985). A negative effect size 
indicates that a greater percentage of the treated cows 
have fewer days open than the untreated cows. Effect 
sizes were calculated for each study. In addition, an 
overall effect size, weighted by sample size, was calcu-
lated. Because the extracted variables were continuous, 
a weighted mean difference and 95% CI were calculated 
for each study outcome (Hedges and Olkin, 1985). 
Variation in experiment level effect size was assessed 
with a χ2 test for heterogeneity (Duffield et al., 2008).
Degree of heterogeneity of results among trials was 
quantified using the I2 statistic (Higgins et al., 2003). 
The I2 statistic describes the percentage of total varia-
tion across studies that is due to heterogeneity rather 







where Q is the χ2 heterogeneity statistic and k is the 
number of trials. Negative values of I2 were made equal 
to zero; consequently, I2 was between 0 and 100%. A 
value greater than 50% may be considered indicative of 
substantial heterogeneity (Duffield et al., 2008).
Because significant heterogeneity was found, results 
were reported using the random effects model and 
potential causes of the heterogeneity were sought. A 
random-effects meta-analysis assumes a normal dis-
tribution of study effects. Sources of heterogeneity 
of response were explored using subgroup analysis. 
Subgroup analysis was prespecified and conducted by 
considering aspects of study design such as the method 
of allocation to treatment and control groups as well 
blinding. In this context, subgroups A and B repre-
sented the randomized and the nonrandomized trials, 
respectively. Blinded trials were allocated to subgroup 
C, whereas subgroup D included those not blinded. In 
addition, subgroups were formed according to the pres-
ence of statistically significant effects and the applied 
PGF2α derivative—dinoprost (subgroup E), clopros-
tenol (subgroup F), or tiaprost (subgroup G). Because 
the randomized trials were those showing statistically 
significant effects, subgroups A and B additionally re-
flected the trials showing significant and nonsignificant 
effects, respectively.
To investigate the possible effect of large weighting 
on the summary estimated effect obtained from the 
meta-analysis, a sensitivity analysis was performed 
considering the effect of a PGF2α treatment on CFSI 
and CCI by eliminating the studies with the largest 
weights one by one.
Forest plots were used to visually display the esti-
mated effect size (Z), 95% CI, and study weights. The 
presence of publication bias was investigated graphi-
cally using funnel plots, in which the size of effect for 
each treatment and control group comparison was plot-
ted against its standard error and the resulting plot 
observed for deficiencies in predicted funnel shape.
RESULTS
In total, 4,393 publications were retrieved (Vetseek, 
2,369; PubMed, 570; Medline, 565; Animal Production, 
889). After excluding duplicates (n = 2,086), 2,307 
publications remained.
Specific exclusion criteria were defined to exclude 
studies that were not written in English or German (n 
= 905) or did not focus on chronic endometritis (i.e., 
equal to and after 21 d after parturition; Sheldon et 
al., 2006) (n = 725). In addition, studies in which the 
animals received concomitant treatments with medica-
tions other than PGF2α were excluded (n = 358). Book 
chapters (n = 44), case studies (n = 36), review articles 
(n = 23), and abstracts (n = 1) were excluded. Fur-
thermore, publications describing etiological, epidemio-
logical, microbiological, or nutritional results, clinical 
symptoms, or diagnostic procedures were rejected (n = 
177). Articles not meeting the inclusion criteria due to 
incorrect indexing, and those not obtainable through 
the internet, bibliographies, or interlibrary lending 
services (n = 32) were excluded as well. If multiple 
publications were retrieved describing the same trial, 
those containing the least information were regarded 
as duplicates and excluded (n = 6). In summary, 2,246 
indexed articles had to be excluded according to the 
exclusion criteria, resulting in 61 remaining publica-
tions comprising 63 individual trials. Because 4 articles 
were retrieved through search by hand, a total of 65 
publications, comprising 68 trials, met the inclusion cri-
teria. After applying the inclusion criteria (i.e., control 
group, calculation of median and SD of CFSI and CCI), 
6 studies were eligible for meta-analytic investigation. 
However, because 1 of the 6 studies only provided data 
concerning CCI, only 5 studies were available for the 
overall investigation of CFSI.
A summary of the studies used for the various analy-
ses concerning reproductive performance after PGF2α 
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treatment is presented in Table 1. Six trials in 5 eligible 
studies had 2,596 cows available to assess the effect 
of a PGF2α treatment in case of chronic endometritis 
on CCI. Because one of those trials did not calculate 
CFSI, only 5 trials in 4 studies with 2,510 cows were 
available to assess the effect of a PGF2α treatment on 
CFSI. Statistical significance was considered to be 0.05.
Over all the trials analyzed, PGF2α treatment in-
creased the CFSI (Z = 2.12, 95% CI = 0.59 to 15.40; 
P = 0.03) and the CCI (Z = 12.35, 95% CI = 16.41 to 
22.61; P < 0.00001) compared with the control group, 
respectively (Table 2).
The 95% CI of individual values (based on SD) 
varied considerably between studies. For 2 trials (Feld-
mann et al., 2005; Hirsbrunner et al., 2006), confidence 
intervals including zero were found, indicating no effect 
of a PGF2α treatment in case of chronic endometritis. 
Concerning overall effect sizes, noticeable confidence 
intervals could be found for either or both reproductive 
performance parameters in the subgroups A, C, E, and 
F. In addition, all of those confidence intervals included 
zero.
Heterogeneity was substantial for CFSI (χ2 = 
1,898.34, df = 4, P < 0.00001, I2 = 100%) and CCI (χ2 
= 37.38, df = 5, P < 0.00001, I2 = 87%). Therefore, 
random effects models were used and sources of hetero-
geneity were explored with a subgroup analysis.
Forest plots illustrating the effect of PGF2α on CFSI 
and CCI are presented in Figure 1. Confidence intervals 
of the single studies did not always overlap, which indi-
cates further evidence of medium to high heterogeneity 
between the studies.
The results of all subgroups were heterogeneous for 
both CCI and CFSI (P ≤ 0.04), except subgroups B 
and G for CCI (P = 0.06; Table 2). Concerning both 
outcomes, significant pooled estimates for subgroups 
including nonrandomized trials (B), nonblinded trials 
(D), and trials administering tiaprost (G) could be 
detected. Although expressed numerically in Table 2, 
Figure 2 shows how the pooled data of 3 (CFSI) or 4 
(CCI) randomized studies provided smaller and non-
significant effect (CFSI: Z = −0.35, P = 0.73; CCI: Z 
= 0.17, P = 0.87) than did the 2 studies that were not 
randomized (CFSI: Z = 8.25, P < 0.00001; CCI: Z = 
34.36, P < 0.00001). Comparing heterogeneity of those 
2 subgroups, significant differences concerning CFSI (P 
= 0.01) as well as CCI (P = 0.04) were detected. Com-
paring trials with (P < 0.05) and without statistically 
significant effects of PGF2α treatment, the only trials 
providing statistical significance were those 2 that did 
not apply any method of randomization. Hence, the 
results found by comparing randomized and nonran-
domized trials equate to those found through subgroup 
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Table 2. Summary of effect sizes (Z), 95% CI, mean differences (MD), between-studies variance (τ2), ratio of true heterogeneity to total 
observed variation (I 2), χ2, and expected variation (df), and P-values for each outcome and subgroup 
Group analyzed1 Z
P-value  
of Z 95% CI MD τ2 I 2 (%) χ2 df
P-value  
of df
Calving to first service interval
 All trials 2.12 0.03 0.59, 15.40 8.00 60.88 100 1,898.34 4 <0.00001
 A −0.35 0.73 −23.61, 16.46 −3.58 284.77 97 72.18 2 <0.00001
 B 8.25 <0.00001 17.87, 29.00 23.44 16.10 100 477.32 1 <0.00001
 C 1.46 0.14 −1.38, 3.38 4.00 NA2 NA NA NA NA
 D 2.15 0.03 0.79, 17.32 9.05 60.02 100 1,857.68 3 <0.00001
 E 0.86 0.39 −10.53, 27.13 8.3 NA NA NA NA NA
 F −0.68 0.50 −31.65, 15.39 −8.13 283.61 98 65.56 1 <0.00001
 G 8.25 <0.00001 17.87, 29.00 8.25 16.10 100 477.32 1 <0.00001
Calving to conception interval
 All trials 12.35 <0.00001 16.41, 22.61 19.51 7.02 87 37.83 5 <0.00001
 A 0.17 0.87 −17.80, 21.15 1.67 333.96 89 27.85 3 <0.00001
 B 34.36 <0.00001 20.96, 23.50 22.23 0.63 73 3.66 1 0.06
 C −0.46 0.65 −15.91, 9.91 −3.00 NA NA NA NA NA
 D 16.14 <0.00001 18.59, 23.73 21.16 4.23 83 23.62 4 <0.0001
 E −0.54 0.59 −38.31, 21.84 −8.24 362.94 77 4.35 1 0.04
 F 0.82 0.41 −13.65, 33.28 9.81 264.11 92 12.06 1 0.0005
 G 34.36 <0.00001 20.96, 23.50 22.23 0.63 73 3.66 1 0.06
1A = randomized trials or trials showing a statistically significant effect; B = nonrandomized trials or trials showing no statistically significant 
effect; C = blinded trials; D = nonblinded trials; E = trials administering dinoprost; F = trials administering cloprostenol; G = trials admin-
istering tiaprost.
2NA: test for heterogeneity was not applicable because only one study administering dinoprost offered data concerning calving to first service 
interval.
Figure 1. Forest plot of the effect of PGF2α on calving to first service interval (top) and calving to conception interval (bottom) in dairy cows 
suffering from chronic endometritis. Each square represents the mean effect size for that study. The upper and lower limit of the line connected 
to the square represents the upper and lower 95% CI for the effect size. The size of the square reflects the relative weighting of the study to the 
overall effect size estimate with larger squares representing greater weight. The diamond at the bottom represents the 95% CI for the overall 
estimate. The solid vertical line represents a mean difference of zero or no effect. Squares located on the left side of this line represent studies 
showing an effect in the group treated with PGF2α, whereas squares located on the right side of this line indicate an effect found in the control 
group. Study or subgroup refers to the first author and year of the publication. 
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cance. Table 2 indicates that only the nonblinded trials 
provided a significant effect for both outcomes (CFSI: 
Z = 2.15, P = 0.03; CCI: Z = 16.14, P < 0.00001). Het-
erogeneity was only significantly different for CCI (P 
= 0.0003; Table 3). Grouping according to the PGF2α 
derivative applied in the treatment group showed that 
only those 2 studies having applied tiaprost could find a 
statistically significant effect concerning both outcomes: 
CFSI (Z = 8.25, P < 0.00001; Figure 3) and CCI (Z = 
34.36, P < 0.00001; Figure 4). Also, for both outcomes, 
except CCI associated with tiaprost treatment, signifi-
cant differences concerning heterogeneity were found 
within each group that included more than one trial 
and therefore allowed an investigation of heterogeneity. 
When investigating subgroup differences, we noticed a 
significant difference concerning heterogeneity between 
the subgroups for CFSI (P = 0.02; Table 2).
Sensitivity analysis, performed by excluding studies 
stepwise, showed that excluding the 2 trials included 
in one study attributed the highest weight and show-
ing consistently outlying results (Mejía and Lacau-
Mengido, 2005) did not improve the homogeneity 
of either outcome (P = 0.29 for CFSI; P = 0.08 for 
CCI). However, in contrast to the significant effect 
sizes (CFSI: Z = 2.12, P = 0.03; CCI: Z = 12.35, P 
< 0.00001) favoring the control group, omitting those 
2 trials resulted in a somewhat reduced effect (CFSI: 
Z = −0.35, P = 0.73; CCI: Z = 0.17, P = 0.87) and a 
Figure 2. Forest plot of the effect of PGF2α on calving to first service interval (top) and calving to conception interval (bottom) in dairy 
cows suffering from chronic endometritis. Subgroups were created according to the manner of allocation to treatment and control groups. Study 
or subgroup refers to the first author and year of the publication. 
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reduction of the variance (CFSI: 8.00 vs. −3.58; CCI: 
19.51 vs. 1.67). Concerning CFSI, this procedure gener-
ated an effect favoring the treatment group instead of 
the control group (Figure 5). Because those 2 trials 
were the only ones not randomized, sensitivity analysis 
showed, in accordance with the results found through 
subgroup analysis, that randomization was influential 
in modifying the effect size of PGF2α treatment (Figure 
2) as well as the size of variance (Tables 3 and 4). 
Regarding CCI, an additional exclusion of the study by 
LeBlanc (2003), which had the third highest weight, led 
to a significant reduction of heterogeneity (P = 0.001; 
Figure 6). In addition, the effect size shifted from a pre-
viously significant effect (Z = 12.35, P < 0.00001) seen 
in the control group to a smaller nonsignificant effect 
(Z = −0.74, P = 0.46) found in the treatment group. 
Concerning CFSI, omitting the only trial that showed a 
positive effect of the PGF2α treatment (LeBlanc, 2003) 
reduced heterogeneity significantly (P = 0.03) and in-
creased the statistically significant effect size (Z = 7.22, 
P < 0.00001; Figure 7).
Especially concerning CCI, the presented funnel 
plots (Figures 8 and 9) suggest a publication bias to-
ward studies with higher standard errors (i.e., usually 
smaller studies) that reported a positive effect on CCI 
after a PGF2α treatment.
DISCUSSION
Prostaglandin F2α has been recommended as the 
treatment of choice for chronic bovine endometritis by 
numerous authors (e.g., Lewis, 1997 and Azawi, 2008) 
and is, in some parts of the world (e.g., Argentina), 
the most common intervention used in veterinary prac-
tice (Mejía and Lacau-Mengido, 2005). Despite the 
reported inconsistency in recent literature concerning 
the effect (Haimerl et al., 2011), the presented signifi-
cant negative effect of PGF2α; that is, an increase in 
Table 3. Differences between the 3 subgroups concerning χ2, the expected variation (df) and its P-value, and 
ratio of true heterogeneity to total observed variation (I 2) regarding calving to first service interval based on 
the 6 included trials (A to G) 
Item χ2 df
P-value  
of df I2 (%)
Randomization (A vs. B) 6.48 1 0.01 84.6
Blinding (C vs. D) 1.01 1 0.32 0.9
Agent (E vs. F vs. G) 8.37 2 0.02 76.1
Figure 3. Forest plot of the effect of PGF2α on calving to first service interval in dairy cows suffering from chronic endometritis. Subgroups 
were created according to the PGF2α derivative applied. Study or subgroup refers to the first author and year of the publication. 
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CFSI and CCI, was surprising. Yet, the presence of 
significant heterogeneity in response was anticipated 
because of the considerable variations not only in the 
study design but also concerning the outcomes in the 
existing literature, as previously shown by Haimerl et 
al. (2011).
In addition to those findings, we revealed further 
variation concerning study design. One might question 
Figure 4. Forest plot of the effect of PGF2α on calving to conception interval in dairy cows suffering from chronic endometritis. Subgroups 
were created according to the PGF2α derivative applied. Study or subgroup refers to the first author and year of the publication. 
Figure 5. Forest plot of the effect of PGF2α on calving to first service interval in dairy cows suffering from chronic endometritis. Results of 
sensitivity analysis after the 2 trials with the highest weight (Mejía and Lacau-Mengido, 2005) had been excluded. Study or subgroup refers to 
the first author and year of the publication. 
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whether the collective analysis of 6 studies with 3 differ-
ent PGF2α derivatives of variable dosages is meaning-
ful (Table 1). However, every study, except the one by 
Feldmann et al. (2005), applied the derivative accord-
ing to the respective product information. Feldmann et 
al. (2005) based their study on the thesis by Tenhagen 
(2001) administering 25 mg of dinoprost but reported a 
dosage of only 5 mg of dinoprost. Therefore, we assume 
that this dose was reported erroneously. Differences 
between dinoprost, dl-cloprostenol, and d-cloprostenol 
concerning their effect on uterine motility have been 
described (Hirsbrunner et al., 1998). Notwithstanding, 
the main effect—luteolysis—followed by the induction 
of estrus and improving the immune response in cows 
with a responsive corpus luteum is present (Kasiman-
ickam et al., 2005). Considering these pharmacological 
effects and assuming that the dosage reported by Feld-
mann et al. (2005) was 25 mg, every study applied the 
derivative at the dosage recommended by the manufac-
turer. Hence, one might hypothesize that, in every case, 
the drug used was effective.
Subgroup analysis based on the chosen groups did not 
identify one exclusive source of heterogeneity. Instead, 
within every subgroup, except subgroups B, E, and G 
concerning CCI, significant heterogeneity, if measur-
able, was still apparent. However, concerning CCI, in 
the subgroup consisting of nonrandomized trials, no 
significant heterogeneity could be found. Both the non-
randomized and randomized trials displayed significant 
heterogeneity when investigating CFSI. However, sig-
nificant differences concerning heterogeneity between 
the 2 subgroups could be found for both reproductive 
performance parameters. Thus, one might hypothesize 
that the heterogeneity found in both subgroups has dif-
ferent sources.
Weights are assigned to each trial’s result accord-
ing to the precision of its treatment effect estimate. 
Trials that have more precise estimates are more heav-
Table 4. Differences between the 3 subgroups concerning χ2, the expected variation (df) and its P-value, and 
ratio of true heterogeneity to total observed variation (I 2) regarding calving to conception interval based on 
the 6 included trials (A to G) 
Item χ2 df
P-value  
of df I2 (%)
Randomization (A vs. B) 4.26 1 0.04 76.5
Blinding (C vs. D) 12.95 1 0.0003 92.3
Agent (E vs. F vs. G) 5.00 2 0.08 60.0
Figure 6. Forest plot of the effect of PGF2α on calving to conception interval in dairy cows suffering from chronic endometritis. Results of 
sensitivity analysis after the 3 trials with the highest weight (LeBlanc, 2003; Mejía and Lacau-Mengido, 2005) had been excluded. Study or 
subgroup refers to the first author and year of the publication. 
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Figure 7. Forest plot of the effect of PGF2α on calving to first service interval in dairy cows suffering from chronic endometritis. Results of 
sensitivity analysis after the only trial showing an effect in the treatment group (LeBlanc, 2003) had been excluded. Study or subgroup refers 
to the first author and year of the publication. 
Figure 8. Funnel plot of PGF2α effect on calving to first service interval for assessing publication bias. MD = mean difference; SE of MD = 
standard error of the standardized mean difference. The vertical dashed line represents the mean effect size. Publication bias may be present if 
an unequal number of studies (particularly smaller weight studies) are plotted on one side of the line.
Journal of Dairy Science Vol. 96 No. 5, 2013
PROSTAGLANDIN F?? TREATMENT OF ENDOMETRITIS 2983
ily weighted. Thus, one might expect that those trials 
having been assigned the highest weights should be 
those of highest quality and therefore provide the most 
reliable results. High-quality trials use blinding and 
random assignment of patients (Cleophas and Zwinder-
man, 2007). The precision of the estimates, however, 
is primarily determined by the number of probands. 
The 2 trials by Mejía and Lacau-Mengido (2005), for 
example, which were attributed the highest weight, did 
not apply any method of randomization but included 
a large number of cows (trial 1, n = 678; trial 2, n = 
1,308). Nevertheless, the meta-analysis literature con-
tains multiple examples of simple data pooling with-
out weighting, which has long been known to be even 
less appropriate than simple weighting by sample size 
(Barker and Carter, 2005).
Some researchers (Lam and Kennedy, 2005; Willich, 
2006) suggested that low-quality studies tend to show 
higher treatment effects. Our results provide support-
ing evidence for this observation. However, our analysis 
comprises too few trials to formulate valid conclusions 
concerning the relationship between sample size and 
quality. Also, other reviews (Kunz and Oxman, 1998) 
do not support this suggestion.
According to Cleophas and Zwinderman (2007), an I2 
value >50% is often used as a cutoff for heterogeneity. 
The high I2 values of CFSI and CCI of 100 and 87%, 
respectively, not only show high inconsistency between 
the studies but also indicate that most of the variability 
across studies is due to heterogeneity rather than to 
chance. Compared with our data, the meta-analysis 
conducted by Duffield et al. (2008) on the effect of mo-
nensin on selected plasma, serum, or blood parameters 
in lactating dairy cattle revealed considerably lower I2 
values, with the highest being 54% for cholesterol.
Significant heterogeneity suggests that the studies 
are not measuring a common population effect and 
that the differences in the study parameters are likely 
responsible for the varying treatment effect (Oxman et 
al., 1994). As mentioned by Lam and Kennedy (2005), 
different schools of thought exist regarding how much 
homogeneity is required for appropriate comparisons. 
Lam and Kennedy (2005) also indicate that there is 
some danger of over-interpreting heterogeneity. Hence, 
heterogeneity may occur by chance and is an important 
possibility when a clinical explanation is not found or 
when the heterogeneity is clinically irrelevant. However, 
a great deal of uniformity among the results of indepen-
dently performed studies is not necessarily good (Rie-
gelman, 2005). Hence, a low heterogeneity might indi-
cate consistency in bias rather than consistency in real 
effects. In contrast, Fourichon et al. (2000) emphasized 
that an overall summary estimate may not be relevant 
if it is based on heterogeneous studies. Concerning the 
Figure 9. Funnel plot of PGF2α effect on calving to conception interval for assessing publication bias. MD = mean difference; SE of MD = 
standard error of the standardized mean difference. The vertical dashed line represents the mean effect size. Publication bias may be present if 
an unequal number of studies (particularly smaller weight studies) are plotted on one side of the line.
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presented meta-analysis, more clinical trials should be 
conducted and included in an updated analysis to learn 
more about the sources of heterogeneity.
Subgroup and sensitivity analysis led to interesting 
findings concerning the summary estimate. Although 
the investigation of all trials showed statistically sig-
nificant overall effect sizes concerning CFSI and CCI, 
significance could not be sustained in the subgroups A 
(randomized trials), C (blinded trials), E (dinoprost), 
and F (cloprostenol). Concerning the randomized and 
blinded trials, this effect may again be explained by 
the assumption made by Willich (2006)—that trials 
revealing a stringent study design tend to display lower 
treatment effects. To support this statement, Figure 2 
illustrates how the pooled data of 3 (CFSI) or 4 (CCI) 
randomized studies provided a smaller and nonsignifi-
cant effect than did 2 studies that did not conduct ran-
domization. Surprisingly, in the case of CFSI, excluding 
nonrandomized trials resulted in a positive effect of the 
treatment instead of control group. Obviously, the sum-
mary result is mainly determined by the nonrandom-
ized studies.
To determine the precision of the effect estimates, 
the 95% CI of individual values (based on SD) was cal-
culated. Concerning overall effect sizes, wide confidence 
intervals were found for CFSI or CCI in the subgroups 
A (CFSI, −23.61, 16.46; CCI, −17.80, 21.15), C (CFSI, 
−1.38, 3.38; CCI, −15.91, 9.91), E (CFSI, −10.53, 
27.13; CCI, −38.31, 21.84) and F (CFSI, −31.65, 15.39; 
CCI, −13.65, 33.28). These findings are surprising as 
they imply that trials with a sound study design did not 
generate a precise effect estimate. Also, in comparison 
to other meta-analyses, the confidence intervals calcu-
lated in our study were wider. Fourichon et al. (2000), 
for example, investigated the effect of various diseases 
on reproduction in dairy cows based on results from 
70 papers. Of all the diseases considered, confidence 
intervals were mainly narrow, except for days open in 
all cows concerning the effect of retained placenta (3.0, 
48.8) and cystic ovaries (−22.8, 47.0), respectively. The 
meta-analysis conducted by Duffield et al. (2008) on the 
effect of monensin, however, revealed large variations 
regarding confidence intervals, ranging from −149.5, 
−78.3 for BHBA to −0.019, 0.037 for calcium.
However, confidence intervals for meta-analyses do 
not depend only on the precision of the individual study 
estimates, but also on the number of studies combined. 
Because the width of the confidence interval usually 
decreases as more studies are added to a meta-analysis 
(Borenstein et al., 2009), the limited number of tri-
als included, especially in the single subgroups, con-
tributed to the magnitude of the confidence intervals. 
This could account for the mainly narrow confidence 
intervals found by Fourichon et al. (2000) because 
that meta-analysis included 70 papers. However, meta-
analytic investigations conducted by Burton and Lean 
(1995) revealed considerably smaller 95% CI (−0.44, 
−0.01) concerning CCI after a PGF treatment of cows 
with an abnormal puerperium, although the number of 
trials included was similar to that in our analysis (n = 
7). In addition, for random-effects models, as used in 
this meta-analysis, precision will decrease with increas-
ing heterogeneity and confidence intervals will widen 
correspondingly. Furthermore, all of those confidence 
intervals include zero, which leads to the assumption 
that the mean effect size does not differ significantly 
from zero (Eisend, 2004). This, in turn, indicates that 
PGF2α treatment has no effect in the case of chronic 
endometritis.
The 95% CI of individual values varied considerably 
between studies, which is further evidence for consid-
erable heterogeneity. Because I2 reflects the extent of 
overlap of confidence intervals, which is not dependent 
on the actual location or the spread of the true effects 
(Borenstein et al., 2009), the high values for I2 are con-
sistent with the limited overlapping of the single confi-
dence intervals. Beyond that, for 2 trials (Feldmann et 
al., 2005; Hirsbrunner et al., 2006), confidence intervals 
including zero were found.
Grouping according to the PGF2α derivative showed 
that only those 2 studies having applied tiaprost could 
find a statistically significant effect concerning both 
outcomes. This was not surprising, however, because 
this subgroup consisted exclusively of the 2 trials exe-
cuted by Mejía and Lacau-Mengido (2005), which were 
those 2 not randomized and solely showing significant 
effect estimates. Therefore, it remains unclear if the 
statistical significance of the effect estimate is due to 
the derivative applied or the differences in study design.
Another essential objective of a meta-analysis is to 
search for potential bias, which may be introduced 
by deficient literature search or selection (Barker and 
Carter, 2005). As shown by several authors (Egger and 
Smith, 1998; Montori et al., 2000; Song et al., 2000), one 
of the most frequently occurring events is the absence 
of studies with “negative” outcomes, which is due to a 
number of reasons. “Negative” trials, or those that fail 
to show superiority of the experimental treatment, tend 
to be left unpublished (publication bias) or published 
more slowly (pipeline bias) and are less frequently 
retrieved by the searching process (retrieval bias). An-
other problem is that “positive” trials are more likely 
to be published more than once, not always in a readily 
identifiable way. Publication bias can have an impor-
tant effect on the outcomes of meta-analyses (Scifres 
et al., 2009). Measuring the effects of publication bias 
quantitatively can be difficult. Nevertheless, various 
approaches exist. The most widely applied method for 
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detecting publication bias in a meta-analysis is the fun-
nel plot, in which the effect size for individual trials is 
plotted against a measure of the precision of the treat-
ment effect estimate, such as the size of the trial (Egger 
et al., 1997). In the present meta-analysis, the measure 
of precision was the standard error. When a funnel plot 
is used to study an unbiased sample of trials, the ob-
served effect sizes should range symmetrically around 
the true effect size, which will be most accurately esti-
mated by the largest trials, thus giving a symmetrical, 
funnel-shaped plot (Barker and Carter, 2005). In the 
conducted meta-analysis, however, such a funnel shape 
was not detected for either CFSI or CCI. Especially 
with regard to CCI, a strong asymmetry was found 
toward studies with higher standard error, reporting a 
positive effect on CCI after a PGF2α treatment. Such 
an asymmetry is often caused by small trials not pro-
viding much evidence of efficacy and therefore being 
infrequently published or retrieved, leading to larger 
estimates of treatment effect being observed in smaller 
trials (Barker and Carter, 2005). However, difficulties 
exist in assessing the shape of a funnel plot when the 
number of trials included is small (Tang and Liu, 2000; 
Sterne and Egger, 2001).
In addition, small trials tend to overestimate treat-
ment effects because of methodological differences 
(either design flaws or more rigorous implementation 
of treatment), causing a false appearance of publica-
tion bias when none actually exists (Schulz et al., 1995; 
Stuck et al., 1998). This “small-study effect” (Kjaergard 
et al., 2001) leads to the paradox that increasing success 
in locating small, unpublished trials may actually bias 
a meta-analysis toward an overestimation of treatment 
effect (Barker and Carter, 2005). Several researchers 
(Sterne et al., 2000; Sutton et al., 2000) have estimated 
that approximately 25 to 50% of meta-analyses may be 
affected by publication bias and that treatment effects 
were overestimated by up to 47% as a result.
Beyond that, the shape of the funnel plot is extremely 
sensitive to the method used to express treatment effect 
and precision. Thus, applying the fixed-effects method 
in the present meta-analysis might have led to different 
results. However, a fixed-effects analysis is only ap-
propriate when the trials are so similar in design and 
execution that one can assume they address the same 
research hypothesis, using the same methods and treat-
ments in the same population, and when the formal 
test of homogeneity demonstrates a lack of heterogene-
ity between the trial results (Barker and Carter, 2005). 
Thus, due to the considerable heterogeneity found in 
this study, a random-effects analysis was conducted as-
suming that the true effect size varied from study to 
study and the summary effect was our estimate of the 
mean of the distribution of effect sizes (Borenstein et 
al., 2009). With reference to heterogeneity, Terrin et al. 
(2003) and Tang and Liu (2000) demonstrated that an 
asymmetrical funnel plot is only related to publication 
bias if the trials included are homogeneous. Hence, the 
results found concerning publication bias have to be 
considered carefully.
The last step in performing a meta-analysis is to as-
sess its robustness with the help of a sensitivity analy-
sis; that is, checking the stability of the results in rela-
tion to the different ways the analysis could reasonably 
be performed (Olkin, 1999). Thus, sensitivity analysis 
strengthens the estimation and interpretation of effects 
obtained from several studies (Fourichon et al., 2000), 
and conclusions derived from meta-analysis that are 
robust to multiple sensitivity analyses gain credibility 
in application to general practice (Barker and Carter, 
2005). Sensitivity analyses can be performed in several 
ways (Barker and Carter, 2005). By excluding the 2 
nonrandomized trails due to the highest weights (Mejía 
and Lacau-Mengido, 2005), we simultaneously investi-
gated the possible effect of large-weight and low-quality 
studies on the summary estimated effect obtained from 
the meta-analysis. This approach led to a considerable 
reduction of effect estimates, accompanied by the loss 
of statistical significance. Remarkably, omitting those 
2 trials resulted in an effect on CFSI seen in treat-
ment instead of the control group. These results clearly 
illustrate that the inclusion criteria applied are an 
important factor in determining the summary result. 
According to Cleophas and Zwinderman (2007), this 
observation leads to the conclusion that the present 
meta-analysis lacks robustness and to the necessity of 
more clinical trials to obtain more reliable results.
Meta-analysis methods have been developed to 
calculate the summary estimates of several studies 
to integrate the available information from different 
source studies and to examine the potential origin of 
heterogeneity of the results. However, the findings of a 
meta-analysis must be considered with caution because 
these methods have been developed to summarize the 
results of randomized, controlled trials. Thus, extend-
ing its use to observational studies must account for 
the variability of study designs and of populations used 
(Fourichon et al., 2000). Therefore, one might favor the 
strict exclusion of nonrandomized trials. However, as 
pointed out by Khan et al. (1996), it may be worth-
while to not completely reject the studies with lower 
methodology because they can be used for assessing 
sensitivity. In addition, not many meta-analyses have 
been carried out in the field of veterinary medicine, for 
several reasons (Holmes, 2004; Arlt et al., 2005), one 
of which is a shortage of randomized, controlled stud-
ies in veterinary medicine (Arlt and Heuwieser, 2005). 
Therefore, if insufficient randomized, controlled trials 
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are available, trials of lower evidence levels should be 
integrated to enhance the power of the meta-analysis.
CONCLUSIONS
Our meta-analysis did not reveal an improvement of 
reproductive performance of cows with endometritis 
after treatment with PGF2α. Therefore, we encourage 
reconsideration of PGF2α as a routine treatment for 
cows with chronic endometritis. This is particularly 
important because a blanket treatment of PGF2α could 
be perceived by the public as unjustified hormone use. 
Furthermore, we conclude that there is a shortage of 
comparable and high-quality studies investigating 
reproductive performance after PGF2α treatment of 
cows with chronic endometritis. Additional confirma-
tory trials are necessary to shed more light on the 
contradictory results published, to assess the practical 
value of the treatment, and to identify the sources of 
heterogeneity. The latter may reveal important aspects 
concerning study quality and applicability of the results 
in livestock research.
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